Fig. 4: Humoral immune responses following NDV-PFS vaccination in K18 mice. | npj Vaccines

Fig. 4: Humoral immune responses following NDV-PFS vaccination in K18 mice.

From: Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges

Fig. 4

K18 transgenic were vaccinated intranasally with NDV-PFS. a WT SARS-CoV-2 spike protein-specific serum IgG endpoint titers in 28 days following each vaccine dose. b WT SARS-CoV-2, Delta, and Omicron (BA.2) neutralization titers 28 days following each vaccine dose. C Neutralization titers against WT SARS-CoV-2, Delta, and Omicron (BA.2) 28 days following the second vaccine dose, with fold differences in mean titer between WT and Delta shown. Reported are Log10 NT50 values. Significance was assessed using two-way ANOVA in b and the Kruskal–Wallis test in (c). ***p = 0.004; ****p < 0.0001. n = 40 for day 21 and n = 20 for samples on day 56. Shown are geometric mean titers + SD and a and b, medians are shown in (c).

Back to article page